Elevance Health, Inc. (NYSE:ELV) Shares Bought by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. grew its stake in Elevance Health, Inc. (NYSE:ELV) by 1.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 43,858 shares of the company’s stock after purchasing an additional 788 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in Elevance Health were worth $20,682,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Alaska Permanent Fund Corp purchased a new position in shares of Elevance Health in the 4th quarter valued at about $31,000. Hexagon Capital Partners LLC lifted its position in shares of Elevance Health by 63.0% in the fourth quarter. Hexagon Capital Partners LLC now owns 75 shares of the company’s stock valued at $35,000 after acquiring an additional 29 shares in the last quarter. ORG Partners LLC purchased a new stake in shares of Elevance Health in the fourth quarter valued at $40,000. Private Wealth Management Group LLC acquired a new position in Elevance Health in the fourth quarter valued at $41,000. Finally, Orion Capital Management LLC acquired a new position in Elevance Health in the third quarter valued at $46,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Price Performance

Shares of Elevance Health stock traded down $22.53 on Monday, hitting $521.41. 1,533,700 shares of the company traded hands, compared to its average volume of 1,013,797. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.54. Elevance Health, Inc. has a 12-month low of $412.00 and a 12-month high of $550.34. The firm’s 50-day simple moving average is $523.89 and its 200 day simple moving average is $498.91. The company has a market cap of $121.19 billion, a P/E ratio of 19.71, a P/E/G ratio of 1.15 and a beta of 0.79.

Elevance Health (NYSE:ELV) last announced its earnings results on Thursday, April 18th. The company reported $10.64 earnings per share for the quarter, beating analysts’ consensus estimates of $10.54 by $0.10. Elevance Health had a net margin of 3.64% and a return on equity of 20.62%. The firm had revenue of $42.27 billion for the quarter, compared to analyst estimates of $42.49 billion. During the same quarter in the previous year, the firm posted $9.46 EPS. The company’s revenue for the quarter was up .9% compared to the same quarter last year. Analysts expect that Elevance Health, Inc. will post 37.26 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 25th. Stockholders of record on Monday, June 10th will be issued a $1.63 dividend. This represents a $6.52 annualized dividend and a dividend yield of 1.25%. The ex-dividend date is Monday, June 10th. Elevance Health’s dividend payout ratio (DPR) is presently 24.64%.

Insider Activity at Elevance Health

In related news, EVP Felicia F. Norwood sold 14,111 shares of Elevance Health stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $533.74, for a total transaction of $7,531,605.14. Following the completion of the sale, the executive vice president now owns 31,460 shares in the company, valued at approximately $16,791,460.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.29% of the stock is owned by insiders.

Wall Street Analyst Weigh In

ELV has been the subject of a number of recent research reports. Jefferies Financial Group increased their target price on Elevance Health from $602.00 to $604.00 and gave the company a “buy” rating in a research note on Friday, April 19th. Mizuho raised their price objective on Elevance Health from $575.00 to $585.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Truist Financial reissued a “buy” rating and set a $600.00 price objective (up previously from $580.00) on shares of Elevance Health in a research report on Friday, April 19th. UBS Group raised their target price on Elevance Health from $585.00 to $605.00 and gave the company a “buy” rating in a report on Friday, April 19th. Finally, Wells Fargo & Company lifted their target price on Elevance Health from $557.00 to $600.00 and gave the stock an “overweight” rating in a research report on Friday, April 19th. One investment analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Elevance Health presently has an average rating of “Buy” and a consensus target price of $587.42.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.